Abstract
The risk connotation of terminology in influencing decision-making should not be underestimated. For example, “superficial” T1HG bladder cancer has the same poor cancer-specific survival as that conferred by the “highest risk” prostate cancer (Gleason 10, T3b). Co-management of concomitant prostate cancer and non-muscle invasive bladder cancer requires a careful competing risk analysis by both the physician and patient. Herein, we detail how patients and physicians should be careful not to underestimate the risk attributed to “non-muscle invasive” bladder cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 39-42 |
Number of pages | 4 |
Journal | Urologic Oncology: Seminars and Original Investigations |
Volume | 36 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2018 |
Keywords
- Bladder cancer
- Prostate cancer
ASJC Scopus subject areas
- Oncology
- Urology